Advanced Endometrial Cancer - Pipeline Insight, 2024

This “Advanced Endometrial Cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Advanced Endometrial Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Advanced Endometrial Cancer Understanding

Advanced Endometrial Cancer: Overview

Metastatic or advanced uterine (endometrial) cancer is a type of cancer that originated in the lining of the uterus (endometrium) and has spread to distant areas of the body. In general, uterine cancer can metastasize to the rectum or bladder. Other areas where it may spread include the vagina, ovaries and fallopian tubes. This form of cancer is typically slow growing and often detected before it has spread to more distant areas of the body. Different types of treatment are available for patients with endometrial cancer. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. Surgery (removing the cancer in an operation) is the most common treatment for endometrial cancer. Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing.

Advanced Endometrial Cancer - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Endometrial Cancer pipeline landscape is provided which includes the disease overview and Advanced Endometrial Cancer treatment guidelines. The assessment part of the report embraces, in depth Advanced Endometrial Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Endometrial Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Endometrial Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Endometrial Cancer.

Advanced Endometrial Cancer Emerging Drugs Chapters

This segment of the Advanced Endometrial Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Endometrial Cancer Emerging Drugs

Retifanlimab: Incyte Corporation Retifanlimab (formerly INCMGA0012), an investigational intravenous PD-1 inhibitor, is currently under evaluation in registration-directed trials as a monotherapy for patients with microsatellite instability-high endometrial cancer, Merkel cell carcinoma and squamous cell carcinoma of the anal canal (SCAC); and in combination with platinum-based chemotherapy for patients with non-small cell lung cancer andSCAC.

Trastuzumab duocarmazine (SYD985): Byondis The most advanced compound in the company’s pipeline is trastuzumab duocarmazine (US non-proprietary name [vic-]trastuzumab duocarmazine). This investigational anti-HER2 ADC, targets a broad range of HER2-expressing cancers such as (metastatic) breast, gastric, bladder (urothelial) and uterine (endometrial) cancer. Trastuzumab duocarmazine could be used in patients where other (anti-HER2) treatments have failed, reflecting our philosophy of developing new, innovative medicines for relentless cancers. Trastuzumab duocarmazine is Byondis’ frontrunner ADC. The antibody, trastuzumab, can bind to a specific protein, HER2 (Human Epidermal growth factor Receptor 2) on the cell surface of tumor cells in many different tumor types. The linker-drug in trastuzumab duocarmazine is vc-seco-DUBA.

Advanced Endometrial Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Endometrial Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Advanced Endometrial Cancer

There are approx. 25+ key companies which are developing the therapies for Advanced Endometrial Cancer. The companies which have their Advanced Endometrial Cancer drug candidates in the most advanced stage, i.e. phase II include, Incyte Corporation.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Advanced Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Endometrial Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Endometrial Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Endometrial Cancer drugs.

Advanced Endometrial Cancer Report Insights

• Advanced Endometrial Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Advanced Endometrial Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Advanced Endometrial Cancer drugs?
• How many Advanced Endometrial Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Endometrial Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Advanced Endometrial Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Advanced Endometrial Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Incyte Corporation
• Byondis B.V.
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Ability Pharmaceuticals SL
• Zymeworks Inc.
• AstraZeneca
• Eli Lilly and Company
• Pfizer
• Karyopharm Therapeutics
• Genentech
• Eli Lilly and Company
• Genentech, Inc.
• NETRIS Pharma
• Five Prime Therapeutics, Inc.
• Millennium Pharmaceuticals, Inc.
• Novartis Oncology
• Takeda
• Mundipharma-EDO GmbH
• Zai Lab (Shanghai) Co., Ltd.
• Haihe Biopharma Co., Ltd.
• Xencor
• Compugen Ltd
• Checkpoint Therapeutics, Inc.
• Celon Pharma SA
• Dragonfly Therapeutics

Key Products

• Retifanlimab
• Bevacizumab
• Abemaciclib
• CYH33
• Niraparib
• EDO-S101
• Trastuzumab duocarmazine
• Serabelisib
• Lacnotuzumab
• TQB2450
• ABTL0812
• DF6002
• Sapanisertib
• COM701
• ZW25
• NP 137
• CK-301
• FPA150
• Cediranib
• LY3484356
• PF-06939999
• Selinexor
• Atezolizumab
• XmAb®23104
• CPL304110

This product will be delivered within 2-4 business days.